Fact Check Friday: The truth about biopharmaceutical patents

| August 26, 2016

article image
Competition is the essence of the biopharmaceutical sector – not monopoly. Even discounting generics for a moment, brand drugs face vigorous competition long before generics arrive on the market. Tufts University researchers have found that the average length of time before a first-in-class drug got its first direct competitor has dropped from 10.2 years in the 1970s to 1.2 years for the period 1990-2003. What’s more, the competitive marketplace in the U.S. has enabled significant cost reductions. For example, Express Scripts recently stated “Hepatitis C is the first example where price is lower in the U.S. vs. Western Europe because of our negotiations.”

Spotlight

Envision Pharma Group

Envision Pharma is an innovative, technology-led scientific communications group. We’re leaders in global publication planning, combining strategic consulting, market access & medical communications expertise, with integrated industry-leading technology solutions including Datavision, Visiontracker and Clear. Working with our partners Pharma, Life Sciences and Bio Tech we help turn vision into reality. Envision Pharma is an innovative, technology-enabled scientific communications group We are the leaders in compliant, global publication planning. Our industry-leading software solutions include Datavision, Visiontracker, and Clear. Envision’s core competencies have evolved to include strategic consulting, market access and medical communications expertise, supported by integrated software solutions. We work together with our partners in Biopharma, to turn vision into reality.

OTHER ARTICLES

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 11, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

A pharma outsourcing mission

Article | August 18, 2021

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Spotlight

Envision Pharma Group

Envision Pharma is an innovative, technology-led scientific communications group. We’re leaders in global publication planning, combining strategic consulting, market access & medical communications expertise, with integrated industry-leading technology solutions including Datavision, Visiontracker and Clear. Working with our partners Pharma, Life Sciences and Bio Tech we help turn vision into reality. Envision Pharma is an innovative, technology-enabled scientific communications group We are the leaders in compliant, global publication planning. Our industry-leading software solutions include Datavision, Visiontracker, and Clear. Envision’s core competencies have evolved to include strategic consulting, market access and medical communications expertise, supported by integrated software solutions. We work together with our partners in Biopharma, to turn vision into reality.

Events